Summary

Novo Nordisk’s roughly 8–10% selloff after REDEFINE 2 looked overly fixated on CagriSema’s 12.6% placebo-adjusted weight loss in patients with diabetes. Sam Fazeli saw efficacy as comparable to Zepbound, while only about 62% reached the highest dose; REDEFINE 1 delivered 22.7%, or roughly 20% placebo-adjusted, with 57% at the top dose. Eric Schmidt’s broader call: “There’s just too much investor focus on singular numbers” when convenience, tolerability and safety may drive commercial differentiation.
BIO CEO John Crowley’s qualified policy thesis was that “on balance there are more positive opportunities than there are threats” for biotechnology. He sees bipartisan recognition of biotech as a strategic asset and pointed to the HHS buyout offer exempting FDA inspectors and reviewers, but urged investors to distinguish “trial balloons,” rhetoric and vulnerable executive orders from durable policy. He also cited the joint address’s omission of drug prices and attacks on pharmaceutical companies as a favorable signal. The National Security Commission on Emerging Biotechnology report expected the week of April 7 could provide actionable proposals on manufacturing, FDA reform and clinical trials.
Crowley rejected a blanket characterization of the administration as anti-science while conceding that vaccines remain a major risk. Sam said he had spoken with a CDC staffer who had been let go and rehired, and that some people were considering leaving rather than participate in another vaccines-and-autism study they regarded as settled; Crowley answered categorically that “there is no link between autism and vaccines” and warned DOGE that taking “a wrecking ball” to scientific agencies could harm patients and effectively surrender the industry to China. He viewed RFK Jr.’s explicit encouragement of measles vaccination as one positive, but limited, data point.
Pricing policy presents both danger and upside: MFN and tariffs threaten economics, while PBM and IRA reforms could improve them. Crowley framed the administration’s MFN position as “not that Americans pay too much for drugs, it’s that other countries pay too little,” while BIO’s survey suggested tariffs could impair access, raise prices and expose dependence on European supply chains. Potential offsets include PBM reform, an orphan-drug fix, removal of the IRA’s nine-versus-13-year “pill penalty,” R&D and orphan tax credits, and the pediatric-disease priority-review voucher.
Crowley said the revised BIOSECURE Act was largely ineffective or toothless and increasingly unlikely to become law, but the strategic contest with China will reshape the sector regardless. Cutting off key partners, particularly manufacturing partners, too quickly could slow research and harm national security; his preferred answer is to “break down our barriers” and incentivize U.S.-and-allied manufacturing. With China potentially reaching “parity or worse” within a couple of years, BIO is pairing domestic policy with deeper links to allies such as Japan.
Obesity dealmaking is shifting from simple acquisition speculation toward portfolio construction and manufacturing readiness. Roche’s 50-50 Zealand Pharma partnership pairs CT-388 with petrelintide, carrying a $1.65 billion upfront and roughly $5.6 billion total economics; Viking separately committed $150 million over three years to CordenPharma for capacity spanning 100 million autoinjectors, 100 million syringes and one billion tablets annually. The hosts did not view Viking’s contract as proof that M&A is dead—it solves a bottleneck under either ownership path.
Small-cap consolidation and long-duration clinical profiles remain attractive where scaled owners can unlock value. Sun Pharma–Checkpoint, BMS–2seventy bio and Jazz–Chimerix reinforced Eric’s view that $100–300 million oncology “onesies and twosies” belong in larger platforms. SpringWorks–Merck KGaA remained unresolved despite Ogsiveo’s successful desmoid-tumor launch, Gomekli’s approval in neurofibromatosis type 1, and consensus sales of $1–$1.5 billion, with perhaps $2 billion of upside. In generalized myasthenia gravis, twice-yearly Uplizna trailed Vyvgart modestly on efficacy measures but could win a role through safety, cost and convenience in a roughly $6 billion and growing market.
BioNTech and Legend now need execution against assets that the market already knows are valuable. BioNTech guided to €2 billion of 2025 revenue versus €2.5 billion consensus and faces €1.5–€1.7 billion of cash burn, making March 28 small-cell lung-cancer survival data crucial to defending enterprise value. Legend’s Carvykti is moving from scarcity toward scale: capacity should double this year, exceed 10,000 doses, and reach 20,000–24,000 annual slots by 2027, ahead of frontline data that might eventually address roughly 9,000 U.S. transplants annually.

Deep dive

Not yet available upstream; scheduled sync will retry.

Jensen Huang & Arthur Mensch: Why Every Nation Needs Its Own AI Strategy No Priors Ep. 107 | With Physical Intelligence Co-Founder Chelsea Finn